Clinical Trials

154 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT04300556 2026-03-13

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

BreastGynecologicThoracic

182 enrolled

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04577833 2026-03-13

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Phase 1 Active not recruiting

136 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04662580 2026-03-13

ARX517

183 enrolled

Prostatic Neoplasms

NCT06353386 2026-03-13

MK-5684-01A

220 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT06717347 2026-03-13

MK-2140-010

1,046 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06925737 2026-03-13

MK-2400-001

1,440 enrolled

Prostatic Neoplasms

NCT07225946 2026-03-13

KLK2-PASenger

800 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT02723994 2026-03-11

A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia

171 enrolled

Burkitt Lymphoma, Leukemia

NCT06091254 2026-03-11

OLYMPIA-1

822 enrolled

Lymphoma, Follicular

NCT06136624 2026-03-11

OMAHA-003

1,310 enrolled

Prostate Cancer Metastatic

NCT06136650 2026-03-09

MK-5684-004

1,314 enrolled

Phase 1/2 Active not recruiting

Prostatic Neoplasms

NCT04623541 2026-03-04

EPCORE™ CLL-1

195 enrolled

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04542824 2026-03-03

EPCORE™ NHL-3

78 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-03-03

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT07005154 2026-03-03

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Phase 2 Recruiting

218 enrolled

Phase 4 Not yet recruiting

Prostatic Neoplasms

NCT07221838 2026-03-03

OCTAGON

75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

NCT01314118 2026-02-24

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

131 enrolled 12 charts

Prostatic Neoplasms

NCT05888493 2026-02-20

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT03407144 2026-02-19

MK-3475-667

340 enrolled

Hodgkin Disease

NCT04569032 2026-02-18

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

82 enrolled 13 charts

Lymphoma, T-Cell, Peripheral

NCT07339267 2026-02-18

A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer

12 enrolled

Prostatic Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT02257736 2026-02-13

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

982 enrolled 15 charts

Prostatic Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT05818683 2026-02-13

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

277 enrolled

Metastatic Castration-resistant Prostate Neoplasms

NCT06356129 2026-02-12

GOLSEEK-1

850 enrolled

Lymphoma

NCT03274492 2026-02-06

POLARIX

1,000 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT06097364 2026-02-06

OLYMPIA-2

733 enrolled

Lymphoma, Follicular, Recurrence

NCT06091865 2026-02-05

OLYMPIA-3

904 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06564038 2026-02-05

Soundtrack-E

276 enrolled

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Mantle-Cell

NCT04729114 2026-02-04

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

174 enrolled

Neoplasm Metastasis, Prostatic Neoplasms

NCT04884035 2026-02-04

Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma

174 enrolled

Lymphoma, B-Cell

NCT03338790 2026-01-27

CheckMate 9KD

292 enrolled 21 charts

Phase 3 Not yet recruiting

Prostatic Neoplasms

NCT07365995 2026-01-26

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

736 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT01995058 2026-01-08

Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

Phase 2 Terminated

54 enrolled 11 charts

Prostatic Neoplasms

NCT06425302 2026-01-08

GOLSEEK-2

90 enrolled

Lymphoma, Lymphoma, Follicular

NCT06568094 2025-12-31

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

100 enrolled

Prostatic Neoplasms

NCT01695005 2025-12-26

A Study of LY3039478 in Participants With Advanced Cancer

Phase 1 Completed

247 enrolled 53 charts

Lymphoma, Neoplasm Metastasis, Neoplasms

NCT03431350 2025-12-23

QUEST

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT02985957 2025-12-22

CheckMate 650

351 enrolled 43 charts

Prostatic Neoplasms

NCT05457257 2025-12-19

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Phase 4 Completed

43 enrolled 16 charts

Phase 1 Active not recruiting

Metastatic Castration-resistant Prostate Cancer

NCT06421935 2025-12-19

M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)

141 enrolled

Gynecologic

Ovarian Neoplasms

NCT04446117 2025-12-18

CONTACT-02

575 enrolled 13 charts

Prostatic Neoplasms

NCT02960022 2025-12-17

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Phase 2 Recruiting

900 enrolled

Prostatic Neoplasms

NCT06911502 2025-12-05

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

400 enrolled